Elevated left ventricular end diastolic pressure, chronic pulmonary oedema and valve disease
Published: April 8, 2024
Abstract Views: 719
PDF: 41
HTML: 100
HTML: 100
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Similar Articles
- Thomas Bernd Dschietzig, Guy Salama, Relaxin-2 for heart failure with preserved ejection fraction: a comment on the termination of a phase-II trial investigating the relaxin-2 analogue, LY3540378 , Global Cardiology: Vol. 2 No. 4 (2024)
- Stefan D. Anker, Javed Butler, Khawaja M. Talha, Tim Friede, Using multiple primary endpoints in clinical trials with a focus on heart failure , Global Cardiology: Vol. 2 No. 2 (2024)
You may also start an advanced similarity search for this article.